Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation
Compared with VMP, D-VMP is unlikely to be a cost-effective regimen for patients with NDMM who are ineligible for ASCT from the US payer's perspective.
Authors
- Dan Xie (ORCID: https://orcid.org/0000-0001-5388-5541)
- Peng-Fei Zhang
Institutions
- Sichuan University (CN)
- West China Second University Hospital of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/bmjopen-2023-076914
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77